15.

Medical therapy strategy for metastatic or unresectable non-transparent cell type RCC (clinical trial preferred in any of the following situations)

Treatment status	Stratification	Level I recommendation	Level II recommendation	Level III recommendation
RCC, renal cell cancer.
First-line treatment	Non-collecting duct carcinoma	Clinical trial	Sunitinib (1A evidence) Everolimus (2A evidence) Temsirolimus (2A evidence) Cabozantinib (2A evidence)	Sorafenib Pazopanib Axitinib
	Collecting duct carcinoma	Clinical trial	Clinical trial	Sorafenib + cis-platinum Sorafenib + gemcitabine + cis-platinum